Researcher comment: The FINCH 1 trial
Bernard Combe takes us through the findings from the FINCH 1 trial of filgotinib in rheumatoid arthritis patients with an inadequate response to methotrexate (7:19).
- News story | Support for filgotinib use in RA patients with inadequate response to methotrexate
- Expert commentary | WATCH: Roy Fleischmann discusses the FINCH 1 results
- Expert commentary | WATCH: John Isaacs discusses the FINCH 1 and FINCH 3 results